{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"HI-E Major"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"HI-E Minor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"HI-P Major"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"HI-P Minor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"HI-N Major"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"HI-N Minor"}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"description":"Response was measured by International Standardized Response Criteria for MDS\n\n* Complete Response: Bone marrow showing \\< 5% myeloblasts with normal maturation of all cell lines; Hgb \\> 11 g/dL (untransfused), ANC ≥1.5 K/L, PLT ≥ 100 K/L, No blasts, no dysplasia\n* Partial remission: All of the CR criteria (if abnormal at baseline), except BM evaluation. Blasts decreased by ≥ 50% over baseline. Cellularity and morphology are not relevant.\n\nHematologic improvement:\n\n* Erythroid (HI-E): For participants with baseline HGB \\< 11g/dL, Major: \\> 2g/dL increase, transfusion independence. Minor: 1-2g/dL increase, ≥ 50% decrease in transfusion requirements\n* Platelet (HI-P): For participants with baseline PLT \\< 100 K/L: Major: absolute increase of \\> 30 K/L, transfusion independence. Minor: ≥ 50% increase (net increase of \\>10 K/L)\n* Neutrophil (HI-N): For participants with baseline ANC \\< 1.5 K/L, Major: \\> 100% increase (net increase \\> 0.5 K/L). Minor: \\> 100% increase (absolute increase \\< 0.5 K/L)","groups":[{"description":"Adult patients with MDS receive treatment with vatalanib.\n\nvatalanib: Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \\> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)","id":"OG000","title":"Vatalanib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 5 years)","title":"Number of Participants With Response","type":"PRIMARY","unitOfMeasure":"participants"}